The main body is a small and flexible T-shaped silicone stent with a storage reservoir surrounding the main trunk, containing levonorgestrel hormone with a drug weight of 52 mg, which is released 20ug per day after being placed in the uterus, and only 10% is released into the blood, the local drug concentration in the endometrium is 1000 times higher than that in the blood circulation, and the local endometrial The endometrial local drug concentration is 1,000 times higher than the blood circulation concentration. The recommended clinical duration of use is 5 years. The decrease in menstrual flow and amenorrhea that occurs is mainly due to the direct inhibitory effect of topical levonorgestrel on the endometrium rather than through the inhibition of ovulatory function of the ovaries. Studies have concluded that ovulation is completely inhibited and ovarian hormones are affected only when intrauterine release is >50ug/day; with 20ug/day, 85% have ovulation. Specific mechanism of action and outstanding advantages: Inhibition of endometrial growth, causing endometrial glandular atrophy, interstitial edema, metaplasia-like changes, vascular inhibition, thinning of the endometrium and reduced menstrual flow. Inhibits endometrial production of prostaglandins and thromboxane, eliminates or reduces spasmodic contractions of uterine smooth muscle, and relieves dysmenorrhea. It also acts on the area of ectopic endometrium, decreasing estrogen receptors in glandular and mesenchymal cells in ectopic lesions, blocking estrogen action, causing the lesions to atrophy or degenerate and the hypertrophic smooth muscle fibers to shrink, thus reducing the size of the uterus and relieving dysmenorrhea. Promoting endometrial reversal, it can transform the hyperplastic overgrown endometrium and reduce the risk of endometrial cancer, etc.; superior to oral progestin, levonorgestrel’s extended-release system LNG-IUS achieves therapeutic effects through local high concentration of progestin, with little impact on ovarian function and mild systemic adverse effects. (Mannorrhea leads to a type of chemical hysterectomy with a positive therapeutic effect on simple hyperplasia, complex hyperplasia and atypical hyperplasia, and its short-term application is safer and better tolerated than oral progestin, especially for patients with endometrial hyperplasia with high malignant potential, which is the greatest benefit. Thickening of cervical mucus; inhibition of sperm motility and function in the uterus and fallopian tubes and prevention of conception have little effect on ovarian function. (Decreased menstrual flow and amenorrhea due to LNG-IUS is mainly due to the inhibitory effect of local LNG on the endometrium, not by suppressing ovarian ovulatory function, when LNG is released intrauterine. 50ug/day to completely inhibit ovulation and affect ovarian hormones; while 85% have ovulation when LNG is released at 20ug/day) Reduces the incidence of pelvic infectious diseases, and has a reversible effect on the endometrium The effect is reversible and fertility can be restored by removal. The outstanding advantages are that the systemic adverse effects are mild, and that Mannaiol does not cause a circulating hypoestrogenic state; compliance is good. It is reversible, long-lasting and economical. Correct placement of the IUD plays an important role in reducing bleeding, but it is not uncommon for the transverse arm of the IUD to become embedded in the endometrium or myometrium if it is not placed properly, which is also a cause of abnormal bleeding. The placement device of the Mannorrhea ring is different from the normal IUDs that have been used for many years. The doctor who places the Mannorrhea ring needs to be specially trained and have some practical experience in order to ensure the correct placement of the Mannorrhea. There are two main forms of bleeding, one is prolonged menstruation and dripping, normal menstruation usually does not exceed 7 days, but after IUD placement, the period may be prolonged to 10 days. More and more clinical studies are now confirming the increasingly widespread non-contraceptive use of Mannorrhea for the prevention and treatment of many gynecological disorders. Mannorrhea is a progestin (levonorgestrel) slow-release system that has a high-tech levonorgestrel slow-release layout locally in the uterus to treat adenomyosis, dysmenorrhea, excessive menstruation, prevent recurrence of endometrial polyps, relieve endometriosis and other diseases, and achieve almost 100% contraceptive effectiveness.